Search Results - "Zettl, U."

Coping with multiple sclerosis—the role of social support by Rommer, P. S., Sühnel, A., König, N., Zettl, U.‐K.

“…Objective The aim of this study was to get insights in mechanisms of coping and social support in multiple sclerosis (MS). Background Multiple sclerosis is the…”
Get full text

Spasticity in patients with multiple sclerosis - clinical characteristics, treatment and quality of life by Flachenecker, P., Henze, T., Zettl, U. K.

“…Aims To gain real‐life data on demographic and clinical characteristics, treatment patterns, treatment satisfaction and quality‐of‐life of multiple…”
Get full text

Cerebrospinal fluid findings in aquaporin-4 antibody positive neuromyelitis optica: Results from 211 lumbar punctures by Jarius, S, Paul, F, Franciotta, D, Ruprecht, K, Ringelstein, M, Bergamaschi, R, Rommer, P, Kleiter, I, Stich, O, Reuss, R, Rauer, S, Zettl, U.K, Wandinger, K.P, Melms, A, Aktas, O, Kristoferitsch, W, Wildemann, B

“…Abstract Background Neuromyelitis optica (NMO, Devic disease) is a severely disabling autoimmune disorder of the CNS, which was considered a subtype of…”
Get full text

Symptomatic treatment in multiple sclerosis—interim analysis of a nationwide registry by Skierlo, S., Rommer, P. S., Zettl, U. K.

“…Objective To analyze symptomatic treatment in patients with multiple sclerosis (MS). Background Multiple sclerosis is a chronic inflammatory disease of the…”
Get full text

CLIPPERS: chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids. Review of an increasingly recognized entity within the spectrum of inflammatory central nervous system disorders by Dudesek, A., Rimmele, F., Tesar, S., Kolbaske, S., Rommer, P. S., Benecke, R., Zettl, U. K.

“…Summary Chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids (CLIPPERS) is a recently defined inflammatory central…”
Get full text

Perceptions on the value of bodily functions in multiple sclerosis by Heesen, C., Haase, R., Melzig, S., Poettgen, J., Berghoff, M., Paul, F., Zettl, U., Marziniak, M., Angstwurm, K., Kern, R., Ziemssen, T., Stellmann, J. P.

“…Background In neurological diseases presenting with a plethora of symptoms, the value of bodily functions for a given patient might be a guide for clinical…”
Get full text

Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patients by Jarius, Sven, Ruprecht, Klemens, Wildemann, Brigitte, Kuempfel, Tania, Ringelstein, Marius, Geis, Christian, Kleiter, Ingo, Kleinschnitz, Christoph, Berthele, Achim, Brettschneider, Johannes, Hellwig, Kerstin, Hemmer, Bernhard, Linker, Ralf A, Lauda, Florian, Mayer, Christoph A, Tumani, Hayrettin, Melms, Arthur, Trebst, Corinna, Stangel, Martin, Marziniak, Martin, Hoffmann, Frank, Schippling, Sven, Faiss, Jürgen H, Neuhaus, Oliver, Ettrich, Barbara, Zentner, Christian, Guthke, Kersten, Hofstadt-van Oy, Ulrich, Reuss, Reinhard, Pellkofer, Hannah, Ziemann, Ulf, Kern, Peter, Wandinger, Klaus P, Bergh, Florian Then, Boettcher, Tobias, Langel, Stefan, Liebetrau, Martin, Rommer, Paulus S, Niehaus, Sabine, Münch, Christoph, Winkelmann, Alexander, Zettl U, Uwe K, Metz, Imke, Veauthier, Christian, Sieb, Jörn P, Wilke, Christian, Hartung, Hans P, Aktas, Orhan, Paul, Friedemann

“…The diagnostic and pathophysiological relevance of antibodies to aquaporin-4 (AQP4-Ab) in patients with neuromyelitis optica spectrum disorders (NMOSD) has…”
Get full text

Monoclonal antibodies in treatment of multiple sclerosis by Rommer, P. S., Dudesek, A., Stüve, O., Zettl, U.K.

“…Summary Monoclonal antibodies (mAbs) are used as therapeutics in a number of disciplines in medicine, such as oncology, rheumatology, gastroenterology,…”
Get full text

Multiple sclerosis treatment and infectious issues: update 2013 by Winkelmann, A., Loebermann, M., Reisinger, E. C., Zettl, U. K.

“…Summary Immunomodulation and immunosuppression are generally linked to an increased risk of infection. In the growing field of new and potent drugs for…”
Get full text

Transcranial brain sonography findings predict disease progression in multiple sclerosis by WALTER, U, WAGNER, S, HOROWSKI, S, BENECKE, R, ZETTL, U. K

“…In multiple sclerosis (MS), an early neurodegenerative affection of subcortical gray matter has been suggested. Transcranial sonography (TCS) shows…”
Get full text

The sphingosine analog fingolimod (FTY720) enhances tone and contractility of rat gastric fundus smooth muscle by Kraft, M., Zettl, U. K., Noack, T., Patejdl, R.

“…Background Sphingosine and its metabolite sphingosine phosphate (S1P) regulate a multitude of biological functions, including the contractile state of smooth…”
Get full text

Neuroinflammation of the central and peripheral nervous system: an update by Stüve, O., Zettl, U.

“…Summary Inflammatory disorders of the peripheral nervous system (PNS) and central nervous system (CNS) are common, and contribute substantially to physical and…”
Get full text

Requirement for safety monitoring for approved multiple sclerosis therapies: an overview by Rommer, P. S., Zettl, U. K., Kieseier, B., Hartung, H.‐P., Menge, T., Frohman, E., Greenberg, B. M., Hemmer, B., Stüve, O.

“…Summary During the last two decades, treatment options for patients with multiple sclerosis (MS) have broadened tremendously. All agents that are currently…”
Get full text

Autoantibodies in autoimmune diseases by Eggert, M, Zettl, U K, Neeck, G

“…The occurrence of autoantibodies is a common feature of autoimmune diseases. This review is intended to give an overview of the most important autoantibodies…”
Get more information

ABC-transporter gene-polymorphisms are potential pharmacogenetic markers for mitoxantrone response in multiple sclerosis by Cotte, S., von Ahsen, N., Kruse, N., Huber, B., Winkelmann, A., Zettl, U. K., Starck, M., König, N., Tellez, N., Dörr, J., Paul, F., Zipp, F., Lühder, F., Koepsell, H., Pannek, H., Montalban, X., Gold, R., Chan, A.

“…Escalation therapy with mitoxantrone (MX) in highly active multiple sclerosis is limited by partially dose-dependent side-effects. Predictors of therapeutic…”
Get full text

Baseline predictors of persistence to first disease‐modifying treatment in multiple sclerosis by Zettl, U. K., Schreiber, H., Bauer‐Steinhusen, U., Glaser, T., Hechenbichler, K., Hecker, M.

“…Objectives Patients with multiple sclerosis (MS) require lifelong therapy. However, success of disease‐modifying therapies is dependent on patients'…”
Get full text

Tyrosine kinase 2 variant influences T lymphocyte polarization and multiple sclerosis susceptibility by COUTURIER, Nicolas, BUCCIARELLI, Florence, GOERTSCHES, Robert H, ZETTL, Uwe K, COMABELLA, Manuel, MONTALBAN, Xavier, RIECKMANN, Peter, WEBER, Frank, MÜLLER-MYHSOK, Bertram, EDAN, Gilles, FONTAINE, Bertrand, MARS, Lennart T, NURTDINOV, Ramil N, SAOUDI, Abdelhadi, OKSENBERG, Jorge R, CLANET, Michel, LIBLAU, Roland S, BRASSAT, David, DEBOUVERIE, Marc, LEBRUN-FRENAY, Christine, DEFER, Gilles, MOREAU, Thibault, CONFAVREUX, Christian, VUKUSIC, Sandra, COURNU-REBEIX, Isabelle

“…The tyrosine kinase 2 variant rs34536443 has been established as a genetic risk factor for multiple sclerosis in a variety of populations. However, the…”
Get full text

Cerebrospinal fluid parameters of B cell-related activity in patients with active disease during natalizumab therapy by Harrer, A, Tumani, H, Niendorf, S, Lauda, F, Geis, C, Weishaupt, A, Kleinschnitz, C, Rauer, S, Kuhle, J, Stangel, M, Weber, F, Uhr, M, Linnebank, M, Wildemann, B, Jarius, S, Guger, M, Ayzenberg, I, Chan, A, Zettl, U, Wiendl, H, Pilz, G, Hitzl, W, Weber, JR, Kraus, J

“…Recently, the disappearance of oligoclonal bands (OCBs) from the cerebrospinal fluid (CSF) of a few natalizumab-treated patients with multiple sclerosis (MS)…”
Get full text

Safety and Clinical Outcomes of Rituximab Treatment in Patients with Multiple Sclerosis and Neuromyelitis Optica: Experience from a National Online Registry (GRAID) by Rommer, P. S., Dörner, T., Freivogel, K., Haas, J., Kieseier, B. C., Kümpfel, T., Paul, F., Proft, F., Schulze-Koops, H., Schmidt, E., Wiendl, H., Ziemann, U., Zettl, U. K.

“…Introduction Multiple sclerosis (MS) is an immune-mediated disease. Over the last decades therapeutic options have broadened tremendously. Nevertheless,…”
Get full text

Effects of intrathecal triamincinolone-acetonide treatment in MS patients with therapy-resistant spasticity by Kamin, F, Rommer, P S, Abu-Mugheisib, M, Koehler, W, Hoffmann, F, Winkelmann, A, Benecke, R, Zettl, U K

“…Objectives: Multiple sclerosis (MS) is an autoimmune disease affecting young people and is a major cause of disability. In the course of time, disability…”
Get full text